# **A Possible Association Between ZNRD1** and Aspirin-Induced Airway **Bronchoconstriction in a Korean Population**

CFA Pasaje,<sup>1,\*</sup> JS Bae,<sup>1,\*</sup> B-L Park,<sup>2</sup> HS Cheong,<sup>2</sup> A-S Jang,<sup>3</sup> S-T Uh,<sup>4</sup> M-K Kim,<sup>5</sup> J-H Kim,<sup>1</sup> T-J Park,<sup>1</sup> J-S Lee,<sup>1</sup> Y Kim,<sup>1</sup> C-S Park,<sup>4</sup> HD Shin<sup>1,2</sup>

<sup>1</sup>Department of Life Science, Sogang University, Seoul, Republic of Korea <sup>2</sup>Department of Genetic Epidemiology, SNP Genetics, Inc., Seoul, Republic of Korea <sup>3</sup>Division of Allergy and Respiratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea <sup>4</sup>Genome Research Center for Allergy and Respiratory Diseases, Division of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea <sup>5</sup>Department of Internal Medicine, Chungbuk National University, College of Medicine, Cheongiu, Republic of Korea

\*Both authors contributed equally to the manuscript

#### Abstract

Background: The etiology of aspirin-exacerbated respiratory disease (AERD) has been attributed to the combination of environmental and genetic risk factors. Although widely investigated in various diseases associated with immune dysfunction, the human zinc ribbon domain containing 1 (ZNRD1) gene is thought to play a role in the pathogenesis of AERD by altering the mechanisms involved in disease development. *Methods:* We selected 6 single-nucleotide polymorphisms (SNPs) for genotyping from the International HapMap database in order to analyze the association between polymorphisms in *ZNRD1* and AERD in a Korean asthma cohort. Genotyping was carried out using the TagMan assay, and differences in genotype frequency distributions were analyzed using logistic regression models.

Results: Nominal associations were found between ZNRD1 rs1150740 and risk of AERD via codominant and dominant genetic inheritance (P=.03; odds ratio, 1.14 [1.14-10.16]). The same polymorphism was found to be significantly associated with a decrease in forced expiratory volume in the first second of expiration, an important diagnostic marker of AERD, even after multiple testing corrections (P=.006, Pcorr=.03 in codominant and dominant models). Conclusions: These preliminary findings suggest a possible relationship between ZNRD1 and aspirin-induced respiratory dysfunctions in a Korean population and provide essential information on the etiology of AERD.

Key words: Aspirin exacerbated respiratory disease. FEV<sub>1</sub>. Haplotype. Single-nucleotide polymorphism. ZNRD1.

#### Resumen

Antecedentes: La etiología de la enfermedad respiratoria exacerbada por AAS (EREA) ha sido atribuida a la combinación de factores de riesgo ambientales y genéticos. Aunque ha sido ampliamente estudiado en varias enfermedades asociadas con trastornos inmunitarios, se considera que el gen ZNRD1 humano desempeña un papel importante en la patogenia de la EREA al afectar a los mecanismos que intervienen en el desarrollo de la enfermedad.

Métodos: Se seleccionaron 6 polimorfismos de un solo nucleótido (SNP) para genotipado de la base de datos International HapMap, con el objeto de analizar la asociación entre las variaciones de ZNRD1 y la EREA en una cohorte de personas de origen coreano con asma. El genotipado se llevó a cabo mediante el ensayo TagMan, y las diferencias en las distribuciones de frecuencia de los genotipos se analizaron mediante modelos de regresión logística.

Resultados: Se observaron asociaciones nominales entre ZNRD1 rs1150740 y el riesgo de EREA por medio de la herencia genética dominante y codominante (p=0,03; OR: 1,14 [1,14-10,16]). Se observó que el mismo polimorfismo estaba significativamente asociado con una disminución del volumen espiratorio máximo en el primer segundo de espiración, un marcador diagnóstico importante de EREA, incluso después de múltiples correcciones de análisis (p = 0,006,  $p^{corr} = 0,03$  en modelos dominantes y codominantes). Conclusiones: Estos hallazgos preliminares indican una posible relación entre ZNRD1 y las disfunciones respiratorias inducidas por AAS en

una población coreana y proporcionan información esencial sobre la etiología de la EREA.

Palabras clave: Enfermedad respiratoria exacerbada por AAS. VEM1. Haplotipo. Polimorfismo de un solo nucleótido. ZNRD1.

# Introduction

Although noted for their medicinal functions, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can induce adverse effects. Aspirin-exacerbated respiratory disease (AERD) is a nonallergic asthma phenotype characterized by aspirin-induced bronchospasm, inflammatory infiltrate in nasal polyp cells, and chronic rhinitis. About 25% of patients with asthma admitted to hospital for mechanical ventilation are aspirin-intolerant [1,2], thus highlighting the role of aspirin in near-fatal asthma attacks. We recently demonstrated an association between the risk of AERD and the following genes: solute carrier family 6 (neurotransmitter transporter, betaine/GABA) member 12 (SLC6A12), emilin/multimerin domain-containing protein 2 (EMID2), and ubiquitin protein ligase E3C (UBE3C) [3-5]. Therefore, previously undiscovered mechanisms could be clinically relevant in aspirin hypersensitivity among asthmatics.

Human zinc ribbon domain containing 1 (ZNRD1; NM\_014596) is a transcription-associated gene on chromosome 6p21.3 spanning more than 3.65 kilobases. This region contains potent markers of AERD, major histocompatibility complex class II DP beta 1 (HLA-DPB1) [6], and tumor necrosis factor  $(TNF) \alpha$  [7], thus implicating the locus in the pathogenesis of AERD. ZNRD1 is a zinc finger-related protein that catalyzes the transcription of DNA into RNA and has been an attractive therapeutic target for various diseases [8,9]. Murine models of airway inflammation reveal decreased levels of zinc in the airway epithelium [10], and supplementation with zinc reduces levels of eosinophils and lymphocytes in bronchial cells [11]. In humans, a significant reduction in zinc levels has been observed in the serum and plasma of asthma patients [12], and zinc has been correlated with the incidence of wheezing among infants [13]. Although the underlying mechanisms remain unclear, ZNRD1 is thought to play a role in respiratory diseases.

*ZNRD1* is a gene of the major histocompatibility complex class 1, a family of molecules that governs immune responses to allergens. Although the immune system has primarily been implicated in allergic asthma, previous reports have revealed associations between components of the immune system and susceptibility to AERD [6,14], suggesting that the immune system may also mediate aspirin-induced bronchospasm in asthmatics.

ZNRD1 has been implicated in diseases associated with immune deficiency, including human immunodeficiency virus (HIV) infection, but not with AERD. By modifying the structure of the mechanisms involved in the development of nonallergic asthma and mapping these mechanisms to an asthma-related locus, ZNRD1 is hypothesized to be a functional and positional marker of AERD. We performed a case-control analysis in a Korean population to investigate a possible association between ZNRD1 and AERD.

# **Materials and Methods**

#### Patients

Asthmatic patients were recruited in Korean hospitals listed in the Asthma Genome Research Center. The Institutional Review Board of each hospital approved the study protocol, and written informed consent was obtained from each patient before blood was drawn. Asthma was diagnosed according to the guidelines of the Global Initiative for Asthma (GINA), with special emphasis on symptoms of dyspnea and wheezing during the last year plus 1 of the following: 1) airway reversibility measured by a positive bronchodilator response, namely, an increase of >15% in forced expiratory volume in the first second of expiration (FEV<sub>1</sub>) or of >12% plus 200 mL following inhalation of a short-acting bronchodilator; 2) airway hyperreactivity to <10 mg/mL of the provocative concentration of methacholine that causes a 20% fall in  $FEV_1$  (PC<sub>20</sub>); or 3) >20% increase in FEV<sub>1</sub> following 2 weeks of treatment with inhaled corticosteroids and long-acting bronchodilators [15]. Pulmonary function tests were performed according to the procedures of the American Thoracic Society [16] using Vmax Series 2130 Autobox Spirometry (Sensor Medics). A skin prick test was performed using 24 common inhalant allergens, atopy was determined as a wheal reaction  $\geq 3 \text{ mm}$ in diameter, and total immunoglobulin (Ig) E was measured using the CAP system (Pharmacia Diagnostics). All patients underwent oral aspirin challenge (OAC) with increasing doses (10 450 mg) [17]. Patients were categorized according to individual reactions to OAC: those exhibiting a  $\geq 20\%$  decrease in FEV1 or a 15% 19% decrease in FEV1 with naso-ocular or cutaneous reactions were considered to have AERD, whereas those exhibiting a <15% decrease in FEV1 with no naso-ocular or cutaneous reactions were considered to have aspirin-tolerant asthma (ATA, controls).

#### Single-Nucleotide Polymorphism Selection and Genotyping

Candidate single-nucleotide polymorphisms (SNP) were selected and screened from the International HapMap Project database according to linkage disequilibrium (LD) status in the Asian population (Chinese Han and Japanese) and minor allele frequencies (MAF >0.05). Genotyping was carried out using polymerase chain reaction (PCR)–based DNA typing in the ABI prism 7900HT sequence detection system (Applied Biosystems) following a TaqMan assay. The assay IDs (Applied Biosystems) and probe sequence of each SNP are described in Supplementary Table 1. Genotyping data quality was assessed by duplicate DNA testing (n=10; rate of concordance in duplicates >99%). Haplotypes were inferred from the successfully genotyped SNPs using the PHASE algorithm, version 2.0 [18].

#### Statistical Analysis

LD between all pairs of biallelic loci was determined using Lewontin's D' (ID'I), and the LD coefficient  $r^2$  was examined using the Haploview algorithm [19]. In order to determine the association between *ZNRD1* and the risk of AERD, logistic regression analysis was carried out with the following covariates: adjusted age (continuous value), sex (male, 0; female, 1), smoking status (nonsmoker, 0; ex-smoker, 1; smoker, 2), atopy (absence, 0; presence, 1), and body mass index. Furthermore, differences in the decline in FEV<sub>1</sub> between the AERD and ATA groups were examined using a regression model controlling for age, sex, smoking status, and atopy as covariates. Data were managed and analyzed using Statistical Analysis System version 9.1 (SAS Inc.). In order achieve optimal correction for multiple testing of markers representing SNPs in LD with each other, we calculated the effective number of independent marker loci (Meff) which accounts for the eigenvalue (spectral) decomposition of all the genotypes represented in the correlation matrix [20] using the SNPSpD program (http://genepi.qimr.edu.au/general/daleN/SNPSpD/). Furthermore, the statistical power of single associations was calculated using the Power for Genetic Association Analyses (PGA) software application [21]. Expression quantitative trait loci (eQTL) analysis was carried out using the eQTL browser (http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/).

# Results

#### Clinical Characteristics of the Study Patients

The clinical profiles of the study patients are shown in Table 1. The study sample comprised 93 patients with AERD (males, 32; females, 61) and 96 controls with ATA (males, 24; females, 72). Significant differences were observed between patients and controls (P=.001) for fall in FEV<sub>1</sub> after OAC (AERD, 23.61% vs ATA, 0.94%), positive rate of aspirin intolerance (AERD, 26.67% vs ATA, 8.42%), and positive rate of nasal polyps (AERD, 63.86% vs ATA, 29.27%) (Table 1). No significant differences were observed between cases and controls for other diagnostic factors.

| Table 1. | Clinical Profiles of the Study Patients <sup>a</sup> |   |
|----------|--|---|
|          |  | - |

| Clinical profile                         | AERD            | ATA             | P Value |
|--|-----------------|-----------------|---------|
| Number of subjects, n                    | 93              | 96              |         |
| Mean age, y (range)                      | 44.39 (17-73)   | 45.79 (15-77)   | .497    |
| Mean age at onset, y (range)             | 38.01 (0-70)    | 37.99 (5-73)    | .995    |
| Sex (male/female)                        | 32/61           | 24/72           | .156    |
| Body mass index, kg/m <sup>2</sup>       | 23.47 (3.18)    | 24.41 (3.29)    | .049    |
| Ex-smoker/current smoker, %              | 15.63/9.38      | 6.45/12.90      | .219    |
| Blood eosinophils, %                     | 6.29 (5.80)     | 4.88 (4.19)     | .060    |
| Predicted FVC, %                         | 89.90 (14.74)   | 87.76 (12.80)   | .293    |
| Predicted FEV <sub>1</sub> , %           | 86.63 (16.74)   | 88.26 (17.04)   | .509    |
| PC <sub>20</sub> methacholine, mg/mL     | 4.23 (7.18)     | 3.04 (4.27)     | .193    |
| Total IgE, IU/mL                         | 321.65 (623.31) | 309.54 (426.04) | .878    |
| Fall rate of FEV1 by aspirin provocation | 23.61 (14.48)   | 0.94 (2.76)     | .001    |
| Positive rate of skin test, %            | 61.46           | 56.99           | .532    |
| Positive rate of aspirin intolerance, %  | 26.67           | 8.42            | .001    |
| Positive rate of nasal polyps, %         | 63.86           | 29.27           | .001    |

Abbreviations: AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; FEV<sub>1</sub>, forced expiratory volume in the first second of expiration; FVC, forced vital capacity; PC<sub>20</sub>, provocative concentration of methacholine that causes a 20% fall in FEV<sub>1</sub>.

<sup>a</sup>Values are expressed with SE unless otherwise indicated

|           |              |        |                      |        |           | MAF     |          |         |
|-----------|--------------|--------|----------------------|--------|-----------|---------|----------|---------|
| Locus     | Position     | Allele | P Value <sup>a</sup> | Korean | Caucasian | Chinese | Japanese | African |
| rs3132129 | 5' near gene | C>T    | .941                 | 0.005  | 0.916     | 0.993   | 1.000    | 0.991   |
| rs3757329 | 5' near gene | A>C    | .648                 | 0.254  | 0.049     | 0.147   | 0.212    | 0.272   |
| rs7769930 | 5' near gene | A>C    | .577                 | 0.227  | 0.062     | 0.148   | 0.163    | _       |
| rs1150741 | Intron 1     | C>G    | .867                 | 0.278  | _         | _       | _        | _       |
| rs1150740 | Intron 3     | G>T    | .491                 | 0.048  | 0.084     | 0.077   | 0.102    | 0.114   |
| rs1150739 | Intron 3     | G>A    | .292                 | 0.471  | 0.363     | 0.438   | 0.597    | 0.404   |

Table 2. Genotype and Allele Distribution of ZNRD1 Variants

Abbreviation: MAF, minor allele frequency.

<sup>a</sup>Values of deviation from Hardy-Weinberg Equilibrium in a Korean population.

#### Distribution of ZNRD1 Variants

With an average call rate of 99.9%, we successfully genotyped 6 ZNRD1 SNPs, including 3 polymorphisms in the 5' near region (rs3132129, rs3757329, and rs7769930) and 3 in the noncoding intronic regions (rs1150741, rs1150740, and rs1150739) (Table 2 and Figure, A). The distribution of each locus was in Hardy-Weinberg Equilibrium (P>.05; Table 2). The LD plot revealed a strong linkage between rs7769930 and rs3757329 ( $r^2$ >0.8; Figure, B and Supplementary Table 2). This finding is of interest, since it may indicate disease susceptibility candidate regions that are unique to specific populations. Three major haplotypes with frequencies >0.05 (Figure, C) were obtained from 1 haplotype block using pairwise comparisons of the genotyped SNPs.  $ZNRD1_ht2$  is unique to the minor allele of rs7769930.

# Association Between ZNRD1 Variants and the Risk of Aspirin Intolerance Among Asthmatics

The results of logistic regression analysis initially revealed a significant association between ZNRD1 rs1150740 and the risk of AERD via codominant and dominant mechanisms (P=.03; odds ratio, 1.14 [1.14-10.16]; Table 3). However, the significant value was not retained after performing multiple testing corrections ( $P^{corr}$ >.05, Table 3) with a Meff of 5.551 extracted from SNPSpD. Since the inferred haplotypes were found to be equivalent to the analyzed SNPs (ht1 with rs1150739, ht2 with rs1150741, and ht3 with rs7769930; Figure, B), analysis of the 3 major haplotypes with frequencies >0.05 revealed the same effect as the polymorphisms tested.

In a further analysis, namely, of the relationship between *ZNRD1* and the fall in FEV<sub>1</sub> after OAC, an important diagnostic marker of AERD was determined using a regression model. The results revealed a significant association between rs1150740 and the decline in FEV<sub>1</sub>, even after multiple comparisons (P=.006,  $P^{\text{corr}}$ =.03 in codominant and dominant models; Table 4).



Figure. Physical map, LD, and haplotypes of the ZNRD1 gene. A, Schematic gene map and single-nucleotide polymorphisms of ZNRD1 on chromosome 6p21.3 (3.65kb). Black blocks represent coding exons and white blocks represent the 5' and 3' untranslated regions. The first base of the translation site was denoted as nucleotide +1. Single-nucleotide polymorphisms in absolute linkage are indicated by brackets ( $r^2$ =1). B, Haplotypes of ZNRD1. C, Linkage disequilibrium coefficient (|D'|) among single-nucleotide polymorphisms of ZNRD1 in a Korean population. Red blocks indicate |D'| = 1, LOD  $\ge 2$ , blue blocks |D'| = 1, LOD < 2 and white blocks |D'| < 1, LOD < 2.

| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$   | •   | V   | MAF  | Co-  | dominant   |                              |                     |                           |                                |                       | Da            |                  | Statistical     |
|---|---|---|--|--|--|------------------------------|---------------------|---------------------------|--------------------------------|-----------------------|---------------|------------------|-----------------|
| $ \frac{r_{122729}{r_{122729}} 0.081 0.091 0.0000 0.0000 0.0000 0.00000 0.00000000$   | Locus   | AERD  | АТА  | OR (95% CI)  | $P^{\mathrm{a}}$                                 | $P^{\mathrm{b}}$             | OR (95% CI)         | $P^{\mathrm{a}}$          | Pcorr                          | UN (72 % CK)          | Ŧ             | Pcorr            | Power           |
| $ \frac{1}{1132739} = 0.411  0.06  0.0144-1.30  3.5  - 0.05  0.0144-1.30  3.5  - 0.05  0.011-1.51  3.0  - 0.01  0.011-1.51  0.01  0.011-1.51  0.011-1.$   | rs3132129   | 0.958   | 0.959  | 1.06 (0.06-17.52)  | 76.  | I                            | 1.06 (0.06-17.52    |                           | I                              | I                     | I             | I                | 11.46           |
| $\frac{770001}{10000} = \frac{1}{000} = \frac{1}{0000} = \frac{1}{0000} = \frac{1}{0000} = \frac{1}{00000} = \frac{1}{000000} = \frac{1}{000000000000000} = \frac{1}{00000000000000000000000000000000000$   | rs3757329   | 0.414   | 0.906  | 0.79 (0.49-1.29)   | 35   | I                            | 0.85 (0.48-1.54)    | 909                       | I                              | 0.42 (0.11-1.57       | . 20          | Ι                | 9,010           |
| $ \frac{1/37741}{123760} 0.087 \text{ int} 0.0651 \text{ is} 0.87 \text{ int} 0.0651 \text{ is} 0.88 \text{ int} 0.01141.010 \text{ int} 0.81 \text{ int} 0.01141.010 \text{ int} 0.01131.012931.0129$  | rs7769930   | 0.911   | 0.404  | 0.79 (0.48-1.29)   | 34   | I                            | 0.84 (0.46-1.54)    | .58                       | I                              | 0.43 (0.12-1.59       |               | I                | 5.760           |
| $\frac{i136720}{i136720}  \frac{i13672}{i13672}  \frac{i136}{i13672}  \frac{i136}{i113671}  \frac{i166}{i113671}  \frac{i136}{i113672}  \frac{i136}{i113672}  \frac{i136}{i113672}  \frac{i136}{i113671}  \frac{i166}{i113671}  $                                     | rs1150741   | 0.940   | 0.872  | 1.04 (0.65-1.65)   | 89   | I                            | 1.07 (0.59-1.91)    | 83                        | I                              | 0.97 (0.31-2.98       | 95            | I                | 8.660           |
| The equivalence of constrained in the equivalent of a state of the interval controlling for age. Set, smoking state, at op, and body mass<br>recting the equivalent of costs and cost states (95% confidence interval) controlling for age. Set, smoking states, at op, and body mass<br>rections. The interval is not significant, OR, odds ratio<br>continuant, and receive mode of logistic regression analyses were used to calculate odds ratios (95% confidence interval) controlling for age. Set, smoking status, at op, and body mass<br>rections.The interval is not significant, OR, odds ratio<br>controlling for age. Set, smoking status, at op, and body mass<br>rections.The interval is not significant, OR, odds ratio<br>controlling for age. Set, smoking status, at op, and body mass<br>rections.The interval is not significant, OR, odds ratioThe interval is not significant, OR, and body mass<br>rections.The interval is not significant, OR, and is not significant, or interval is not significant, and not sensely on the interval is not sensely on the interval is not sensely on the interval interval interval interval interval.The interval is not sensely on the interval int  | re1150740   | 0.466   | 0.703  | 3 40 (1 14-10 16)  | .03  | SN                           | 3 40 (1 14-10 16    | .03<br>03                 | NC                             |                       |               |                  | 17 40           |
| Abreviations: C1, confidence interval: MS, not significant: OR, odds ratio. Abreviations: C1, confidence interval: MS, not significant: OR, odds ratio.   Gene. N11, M2, and M23 were equivalent to sr150293; n1150741, and M2768930, respectively. Apreviations: C1, confidence interval: On trolling for age, sex, smoking status, atopy, and body mass intervals of ingistic regression analyses were used to calculate odds ratios (95% confidence interval) controlling for age, sex, smoking status, atopy, and body mass were specified in the sting corrections (Meff =5.551).   PValues after multiple testing corrections (Meff =5.551). Provine Participation Participation Providence interval) controlling for age, sex, smoking status, atopy, and body mass mass interval.   PACIL OC CR R/R Participation Participation Participation   PACIL OC CR R/R Participation Participation Participation Participation   PACIL OC CR R/R Participation Participation Participation Participation Participation   PACIL C CR R/R Participation  | rs1150739   | 0.469   | 0.451  | 1.18 (0.79-1.77)   | .63<br>.43                                       | Ê I                          | 1.28 (0.67-2.46     |                           |                                | 1.22 (0.61-2.42       | .) .58        |                  | 50.44           |
| Palues after multiple resting corrections (Mert=5.501).<br>Table 4. Regression Analysis of ZVRD1 Polymorphisms and Haplotypes With Fall Rate of FEV, After Oral Aspirin Provocation<br>Locus C/C C/R R/R $Pa^{r}$ $Pa^{rmh}$ $Pb^{r}$ $Pb^{rmh}$ $Pc^{r}$ $Pc^{rmh}$<br>rs3132129 185 (12.06 [15.47]) 2.7(5.04.10.61) - (14.85.42.1.13) 2.74 - (3.90) - (3.9   | Abbreviations: d<br><sup>a</sup> Codominant, d<br>index. <i>ht1</i> , <i>ht2</i> ,<br><sup>b</sup> <i>P</i> <.05. | Cl, confidence ir<br>lominant, and rε<br>and <i>ht3</i> were ec | nterval; NS, no<br>ecessive mode<br>quivalent to <i>rs</i> | ot significant; OR, odds<br>els of logistic regression<br>si 150739, rs 1150741, a | ratio.<br>1 analyses we<br>1nd <i>rs776993</i> ( | ere used to<br>2, respective | calculate odds rati | ios (95% con <sup>-</sup> | fidence interv                 | al) controlling for a | ge, sex, smok | ing status, atop | , and body mass |
| LocusC/CC/RR/R $Pa^a$ $Pa^{anrb}$ $Pb^a$ $Pb^{anrb}$ $Pb^{anrb}$ $Pc^a$ $Pc^{anrb}$ $rs3132129$ 185 (12.06 [15.47])2 (7.50±10.61)7171 $rs375329$ 104 (11.55 [15.05])74 (12.44±14.98)111 (14.85±21.13).748075- $rs776930$ 113 (11.72 [15.15))63 (12.05±14.98)111 (14.85±21.13).829074- $rs1150741$ 97 (12.07 [15.15))63 (12.05±14.98)114 (9.33±10.18).359074- $rs1150740$ 170 (11.07 [14.70))18 (21.23±14.98)114 (9.33±10.18).359074- $rs1150740$ 170 (11.07 [14.70))18 (21.23±14.98)14 (9.33±10.18).359074- $rs1150740$ 170 (11.07 [14.70))18 (21.23±18.22)0.006.03.006.03.006.3760- $rs1150740$ 76 (11.77 [15.89])86 (11.81±14.31)45 (12.70±17.10).5667.67.606060.60 $rs1150740$ 76 (11.07 [14.70)86 (11.81±14.31)45 (12.70±17.10).5667.60<  | <b>Table 4</b> . Regres   | sion Analysis of  | ZNRD1 Poly   | morphisms and Haplot   | types With Fa                                    | ll Rate of Fi                | EV1 After Oral Asp. | irin Provocati            | uo                             |                       |               |                  |                 |
| rs3132129185 (12.06 [15.47])2 (7.50±10.61)717171rs375329104 (11.55 [15.05])74 (12.44±14.98)111 (14.85±21.13).748075-rs776930113 (11.72 [15.15])63 (12.05±14.98)111 (14.85±21.13).829074-rs175074197 (12.93 [16.39])76 (11.33±14.98)14 (9.33±10.18).354937-rs1150740170 (11.07 [14.70])18 (21.23±18.82)0.006.03.006.036760-rs115073956 (11.77 [15.89])86 (11.81±14.31)45 (12.70±17.10).5667606760-Abbreviations: C/C, major homozygote; C/R, heterozygote; R/R minor homozygote5667.67.5060.03.601.61.60.61.600.61.61.600.61.61.61.600.61   | Locus   | 0   | c/c  | C/R  |  |                              | R/R                 | $Pa^{a}$                  | $P\mathrm{a}^{corr\mathrm{b}}$ | $Pb^{\mathrm{a}}$     | $Pb^{corrb}$  | $Pc^{a}$         | $Pc^{corrb}$    |
| $rs3757329$ $104 (11.55 [15.05])$ $74 (12.44\pm14.98)$ $11 (14.85\pm21.13)$ $74$ $ 80$ $ 75$ $ rs776930$ $113 (11.72 [15.15])$ $63 (12.05\pm14.98)$ $11 (14.85\pm21.13)$ $82$ $ 90$ $ 74$ $ rs1150741$ $97 (12.93 [16.39])$ $76 (11.33\pm14.98)$ $11 (14.85\pm21.13)$ $82$ $ 90$ $ 37$ $ rs1150740$ $170 (11.07 [14.70])$ $18 (21.23\pm18.82)$ $0$ $0.06$ $0.3$ $006$ $0.3$ $006$ $0.3$ $ 67$ $ .60$ $rs1150739$ $56 (11.77 [15.89])$ $86 (11.81\pm14.31)$ $45 (12.70\pm17.10)$ $.56$ $ .67$ $ .60$ $ .67$ $ .60$ $-$ Abbreviations: $C/C$ , major homozygote; $R/R$ minor homozygote. $ .67$ $ .67$ $ .60$ $-$ <   | rs3132129   | 185 (12.0   | 06 [15.47])  | 2 (7.50±10   | .(61)  | I                            |                     | .71                       | I                              | .71                   | I             | I                | I               |
| $rs7769930$ $113(11.72[15.15])$ $63(12.05\pm14.98)$ $11(14.85\pm21.13)$ $82$ $ .90$ $ .74$ $ rs1150741$ $97(12.93[16.39])$ $76(11.33\pm14.98)$ $14(9.33\pm10.18)$ $.35$ $ .49$ $ .37$ $ rs1150740$ $170(11.07[14.70])$ $18(21.23\pm18.82)$ $0$ $.006$ $.03$ $.006$ $.03$ $ .67$ $ .60$ $rs1150739$ $56(11.77[15.89])$ $86(11.81\pm14.31)$ $45(12.70\pm17.10)$ $.56$ $ .67$ $ .60$ $ .67$ $ .60$ $ .67$ $ .60$ $ .60$ $ .60$ $ .60$ $ .60$ $ .67$ $ .60$ $.60$ <t< td=""><td>rs3757329</td><td>104 (11.:</td><td>55 [15.05])</td><td>74 (12.44±1</td><td>(4.98)</td><td>11 (1-</td><td><math>4.85\pm 21.13</math></td><td>.74</td><td>Ι</td><td>.80</td><td>I</td><td>.75</td><td>I</td></t<>  | rs3757329   | 104 (11.:   | 55 [15.05])  | 74 (12.44±1  | (4.98)   | 11 (1-                       | $4.85\pm 21.13$     | .74                       | Ι                              | .80                   | I             | .75              | I               |
| $ \frac{r_{s}l15074l}{r_{s}l15074l} \begin{array}{ccccc} 97 (12.93 \ [16.39]) \\ 76 (11.07 \ [14.70]) \\ 86 (11.77 \ [15.89]) \\ 86 (11.77 \ [15.89]) \\ 86 (11.77 \ [15.89]) \\ 86 (11.77 \ [15.89]) \\ 86 (11.81 \pm 14.31) \\ 45 (12.70 \pm 17.10) \\ 56 \\ - \\ - \\ .006 \\ .03 \\ .006 \\ .03 \\ .006 \\ .03 \\ - \\ .03 \\ .006 \\ .03 \\ - \\ .03 \\ - \\ .006 \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .006 \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .03 \\ - \\ .006 \\ - \\ .00$ | rs7769930   | 113 (11.1   | 72 [15.15])  | 63 (12.05±1  | (4.98)   | 11 (1-                       | $4.85\pm21.13$      | .82                       | I                              | 06.                   | I             | .74              | Ι               |
| $ \frac{rs l150740}{rs l150739}  170 (11.07 [14.70])  18 (21.23\pm18.82)  0  006  0.03  0.06  0.03  -  -  -  -  -  -  -  -  -  $  | rs1150741   | 97 (12.   | 93 [16.39])  | 76 (11.33±1  | 4.98)  | 14 (9                        | .33±10.18)          | .35                       | Ι                              | .49                   | I             | .37              | Ι               |
| <i>rs1150739</i> 56 (11.77 [15.89]) 86 (11.81 $\pm$ 14.31) 45 (12.70 $\pm$ 17.10) 56 – .67 – .67 – .60 – . Abbreviations: <i>C/C</i> , major homozygote; <i>R/R</i> minor homozygote.<br>Abbreviations: <i>C/C</i> , major homozygote; <i>C/R</i> , heterozygote; <i>R/R</i> minor homozygote.<br>Codominant, dominant, and recessive models was used for multiple linear regression analyses controlling for age, sex, smoking status, atopy and body mass index. Mean (SD) of the natural logarithmic ratio of each genotype is shown in parenthesis.<br><i>ht1</i> , <i>ht2</i> , and <i>ht3</i> were equivalent with <i>rs1150739</i> , <i>rs1150741</i> , and <i>rs7769930</i> , respectively.   | rs1150740   | 170 (11.0   | 07 [14.70])  | 18 (21.23±1  | (8.82)   | 0                            | ~                   | .006                      | .03                            | 900.                  | .03           | I                | I               |
| Abbreviations: C/C, major homozygote; C/R, heterozygote; R/R minor homozygote.<br><sup>•</sup> Codominant, dominant, and recessive models was used for multiple linear regression analyses controlling for age, sex, smoking status, atopy and body mass index. Mean (SD) of<br>the natural logarithmic ratio of each genotype is shown in parenthesis.<br><i>ht1, ht2,</i> and <i>ht3</i> were equivalent with <i>rs1150739, rs1150741</i> , and <i>rs7769930</i> , respectively.  | rs1150739   | 56 (11.'  | 77 [15.89])  | 86 (11.81±1  | (4.31)   | 45 (1                        | 2.70±17.10)         | .56                       | I                              | .67                   | I             | .60              | Ι               |
| community would and recessive mouses was used for multiple must regression analyses controlling for age, sex, surround status, aropy and body mass much. Mean (5D) of the natural logarithmic ratio of each genotype is shown in parenthesis. <i>ht1</i> , <i>ht2</i> , and <i>ht3</i> were equivalent with rs <i>1150739</i> , rs <i>1150741</i> , and <i>rs7769930</i> , respectively.  | Abbreviations   | : C/C, major h  | nomozygote;  | ; C/R, heterozygote;   | R/R minor I                                      | homozygo                     | te.                 | tuolling for              |                                | oltine status star    | mpod boo m    | M webri soom     | foon (CD) of    |
| ht1, ht2, and ht3 were equivalent with rs1150739, rs1150741, and rs7769930, respectively.   | the natural lo  | garithmic ratic   | of each gen  | otype is shown in pa   | arenthesis.                                      | רמו ועצועטר                  |                     | Intoung to                | agv, ovv, uu                   | UNITE oracuo, und     | py and over   |                  | יה (תה) וואסו   |
|   | ht1, ht2, and   | ht3 were equiv  | valent with r  | s1150739, rs115074.  | l, and rs776                                     | 59930, resl                  | oectively.          |                           |                                |                       |               |                  |                 |

# Discussion

AERD has been attributed to overproduction of cysteinylleukotrienes resulting from inhibition of the cyclooxygenase-2 pathway and diversion of arachidonic acid metabolites towards the 5-lipoxygenase pathway. Aside from the traditional theory of disease development, case-control studies have shown that the mechanisms of immune inflammatory response are implicated in the risk of AERD [6,7,22]. However, the exact role of the immune system in aspirin-induced bronchospasm remains controversial, owing to the lack of known antigen during disease onset.

The ZNRD1 gene has been analyzed extensively in studies on the pathophysiology of HIV infection [23], a disease that is associated with immune system dysfunction. Furthermore, immunochemical analysis has revealed increased expression of ZNRD1 in multidrug-resistant gastric cancer cells [24]. Since aspirin is increasingly used as a means of reducing the risk of gastric cancer [25], a possible link between ZNRD1 and AERD could be established. Decreased levels of zinc in the airways of mice and humans with chronic inflammation provide further evidence that ZNRD1 may be involved in bronchial hyperresponsiveness.

In line with previous reports [26], we observed a female predominance among the AERD patients enrolled in this study. The etiology of airway inflammation has demonstrated relationships between the development of nasal polyps, asthma, and aspirin-intolerance [26]. The clinical history of the study patients revealed significantly more nasal polyps in the AERD group than in the ATA group. Furthermore, it is worth noting that the fall in FEV<sub>1</sub> after OAC was significantly greater in AERD patients than in ATA patients, thus supporting reports that FEV<sub>1</sub> is an important diagnostic marker of the disease.

To our knowledge, this is the first study to present the results of an association analysis of *ZNRD1* and the risk of

AERD. We found that *rs1150740* was nominally associated with the risk of AERD, suggesting that this polymorphism could play a role in aspirin-induced bronchoconstriction among Korean asthmatics. However, since we detected a low association signal and the effect of polymorphisms varies according to ethnicity and geographic location, further investigations in different cohorts are warranted.

FEV<sub>1</sub> is the most common parameter in assessing bronchodilation. A low FEV<sub>1</sub> rate has been consistently associated with AERD and other types of airway disease. Proper interpretation of the decrease in FEV<sub>1</sub> is crucial in the management of airway obstruction. In this study, *ZNRD1 rs1150740*, which was observed to be marginally associated with the risk of AERD, was also found to be significantly associated with the decline in FEV<sub>1</sub>. Patients who were heterozygous for the rare allele (C/R genotype) of the polymorphism were at a higher risk of airway obstruction than patients with other genotypes (C/C and R/R). Since the association signal remained significant after correction, *rs1150740* is expected to facilitate exacerbation of airway inflammation after ingestion of aspirin.

Coordinated regulation of transcription and splicing is key to the development and progression of various disorders. A previous report revealed that polymorphisms in the intronic regions of the gene may induce exon skipping, activate cryptic spliced sites, or affect efficient intron splicing processivity [27], resulting in synthesis of proteins that influence disease pathophysiology. In an attempt to understand whether any of the variants studied can serve as eQTLs and regulate expression levels of *ZNRD1*, further analysis was performed using the eQTL browser. Although the results reveal that *rs1150741* may be a cis-acting regulatory element to LOC347981 (eQTL score, 9.45) and Hs.519979 (eQTL score, 14.22), none of the SNPs tested function directly as potential regulators for *ZNRD1* expression (data not shown).

| Locus     | Assay IDa and Probe Sequence <sup>a</sup> | Probe Sequence |
|-----------|---|----------------|
| rs3132129 | C27463053_10                              | _              |
| rs3757329 | C27477758_10                              | _              |
| rs7769930 | C25924715_20                              | -              |
| rs1150741 | GGCGGTTGTACATTTGGTCT                      | Forward        |
|           | TCAAAGTCTGCACAGGCAAG                      | Reverse        |
|           | GTCAGCTCTCTCTGGT                          | Probe-1 (VIC)  |
|           | GTCAGCTGTCTCTGG                           | Probe-2 (FAM)  |
| rs1150740 | TTGACTGCGGTTGAAGACTG                      | Forward        |
|           | TCCCAAAGTGCTGGGATTAC                      | Reverse        |
|           | CTTATGTTGTTTTTTT                          | Probe-1 (VIC)  |
|           | CTTATGTTTTTTTTT                           | Probe-2 (FAM)  |
| rs1150739 | CAGCAGCATCAGACACACAA                      | Forward        |
|           | TTCCATGTCACTAATTCTGTCTTCA                 | Reverse        |
|           | AGAATTATGAGACATA                          | Probe-1 (VIC)  |
|           | AGAATTATAAGACAT                           | Probe-2 (FAM)  |

Supplementary Table 1. Assay Information of ZNRD1 Single-Nucleotide Polymorphisms

<sup>a</sup>Taqman assay IDs from Applied Biosystems.

|   |           | rs3132129 | rs3757329 | rs7769930 | rs1150741 | rs1150740 | rs1150739 |
|---|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
|   | rs3132129 | _         | 0.049     | 0.084     | 1         | 1         | 1         |
|   | rs3757329 | 0         | _         | 1         | 1         | 1         | 1         |
| 2 | rs7769930 | 0         | 0.864     | _         | 1         | 1         | 1         |
|   | rs1150741 | 0.002     | 0.131     | 0.113     | _         | 1         | 1         |
|   | rs1150740 | 0         | 0.016     | 0.014     | 0.018     | _         | 1         |
|   | rs1150739 | 0.006     | 0.303     | 0.261     | 0.342     | 0.054     | _         |
|   |           |           |           |           |           |           |           |

Supplementary Table 2. Measures of Linkage Disequilibrium Among the Tested ZNRD1 Single-Nucleotide Polymorphisms

Findings from power calculations of single associations showed that the average statistical power to detect effect sizes with the current sample size is 17.37% (Table 3). Furthermore, the possibility that the signal detected could only be a marker for the region and that genes flanking *ZNRD1* could be responsible for the association effect cannot be ruled out. In order to address these limitations, further analyses using larger sample sizes are warranted.

To conclude, findings from this study indicate a possible role of *ZNRD1* in aspirin-induced respiratory dysfunctions in a Korean population. Although future replications and exact functional analyses are needed to confirm the function of *ZNRD1* in the pathogenesis of AERD, these preliminary results can provide crucial supporting information on the genetic etiology of aspirin-hypersensitive airway inflammation.

# Acknowledgments

This work was supported by Korea Science and Engineering Foundation (KOSEF), which is funded by the Korean government (MEST) (No. 2009-0080157), and a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A010249). The DNA samples were generously provided by Soonchunhyang University, Bucheon Hospital Biobank, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs, Republic of Korea.

The authors declare no competing interests.

### References

- Picado C, Castillo JA, Montserrat JM, Agusti-Vidal A. Aspirinintolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J. 1989;2(2):127-9.
- Marquette CH, Saulnier F, Leroy O, Wallaert B, Chopin C, Demarcq JM, Durocher A, Tonnel AB. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis. 1992;146(1):76-81.
- 3. Pasaje CF, Kim JH, Park BL, Cheong HS, Chun JY, Park TJ, Lee

JS, Kim Y, Bae JS, Park JS, Yoon SH, Uh ST, Choi JS, Kim YH, Kim MK, Choi IS, Cho SH, Choi BW, Park CS, Shin HD. Association of SLC6A12 variants with aspirin-intolerant asthma in a Korean population. Ann Hum Genet. 2010;74(4):326-34.

- Pasaje CF, Kim JH, Park BL, Cheong HS, Kim MK, Choi IS, Cho SH, Hong CS, Lee YW, Lee JY, Koh IS, Park TJ, Lee JS, Kim Y, Bae JS, Park CS, Shin HD. A possible association of EMID2 polymorphisms with aspirin hypersensitivity in asthma. Immunogenetics. 2010;63(1):13-21.
- Lee JS, Kim JH, Bae JS, Kim JY, Park TJ, Pasaje CF, Park BL, Cheong HS, Park JS, Uh ST, Kim MK, Choi IS, Cho SH, Choi BW, Park CS, Shin HD. Association analysis of UBE3C polymorphisms in Korean aspirin-intolerant asthmatic patients. Ann Allergy Asthma Immunol. 2010;105(4):307-12.
- Choi JH, Lee KW, Oh HB, Lee KJ, Suh YJ, Park CS, Park HS. HLA association in aspirin-intolerant asthma: DPB1\*0301 as a strong marker in a Korean population. J Allergy Clin Immunol. 2004;113(3):562-4.
- Kim SH, Ye YM, Lee SK, Choi JH, Holloway JW, Park CS, Park HS. Association of TNF-alpha genetic polymorphism with HLA DPB1\*0301. Clin Exp Allergy. 2006;36(10):1247-53.
- 8. Guo W, Zhao YP, Jiang YG, Wang RW, Hong L, Fan DM. Upregulation of ZNRD1 enhances cisplatin resistance in human esophageal cancer cells by regulation of ERCC1 and Bcl-2. Tumour Biol. 2008;29(3):188-94.
- Hong L, Ning X, Shi Y, Shen H, Zhang Y, Lan M, Liang S, Wang J, Fan D. Reversal of multidrug resistance of gastric cancer cells by down-regulation of ZNRD1 with ZNRD1 siRNA. Br J Biomed Sci. 2004;61(4):206-10.
- Truong-Tran AQ, Ruffin RE, Foster PS, Koskinen AM, Coyle P, Philcox JC, Rofe AM, Zalewski PD. Altered zinc homeostasis and caspase-3 activity in murine allergic airway inflammation. Am J Respir Cell Mol Biol. 2002;27(3):286-96.
- Lang C, Murgia C, Leong M, Tan LW, Perozzi G, Knight D, Ruffin R, Zalewski P. Anti-inflammatory effects of zinc and alterations in zinc transporter mRNA in mouse models of allergic inflammation. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):L577-84.
- Murgia N, Muzi G, Dell' Omo M, Montuschi P, Melchiorri D, Ciabattoni G, Abbritti EP, Orazi N, Sapia IE, Abbritti G. Induced sputum, exhaled breath condensate and nasal lavage fluid in electroplating workers exposed to chromium. Int J Immunopathol Pharmacol. 2006;19(4 Suppl):67-71.
- 13. Tahan F, Karakukcu C. Zinc status in infantile wheezing. Pediatr Pulmonol. 2006;41(7):630-4.

- 14. Lee SH, Rhim T, Choi YS, Min JW, Kim SH, Cho SY, Paik YK, Park CS. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med. 2006;173(4):370-8.
- 15. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161(1):309-29.
- 16. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152(3):1107-36.
- 17. Cormican LJ, Farooque S, Altmann DR, Lee TH. Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity. Clin Exp Allergy. 2005;35(6):717-22.
- Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978-89.
- Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-5.
- 20. Nyholt DR. A simple correction for multiple testing for singlenucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74(4):765-9.
- 21. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. BMC Genet. 2008;9:36.
- 22. Berce V, Repnik K, Potocnik U. Association of CCR5-delta32 mutation with reduced risk of nonatopic asthma in Slovenian children. J Asthma. 2008;45(9):780-4.
- 23. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. Human

hematopoietic stem/progenitor cells modified by zincfinger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010;28(8):839-47.

- 24. Zhang YM, Zhao YQ, Pan YL, Shi YQ, Jin XH, Yi H, Fan DM. Effect of ZNRD1 gene antisense RNA on drug resistant gastric cancer cells. World J Gastroenterol. 2003;9(5):894-8.
- 25. Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, Wu XT. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci. 2010;55(6):1533-9.
- 26. Samter M, Beers RF, Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968;68(5):975-83.
- 27. Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004;5(5):389-96.

# Manuscript received September 17, 2011; accepted for publication November 30, 2011.

#### Hyoung Doo Shin

Department of Life Science Sogang University Seoul, 121-742, Republic of Korea E-mail: hdshin@sogang.ac.kr

#### **Choon-Sik Park**

Division of Allergy and Respiratory Medicine Soonchunhyang University Bucheon Hospital Bucheon, 420-767, Republic of Korea E-mail: schalr@schbc.ac.kr